[go: up one dir, main page]

HK1247843A1 - 具有受控吸收曲线的用於口服给药活性剂的制剂 - Google Patents

具有受控吸收曲线的用於口服给药活性剂的制剂 Download PDF

Info

Publication number
HK1247843A1
HK1247843A1 HK18107403.6A HK18107403A HK1247843A1 HK 1247843 A1 HK1247843 A1 HK 1247843A1 HK 18107403 A HK18107403 A HK 18107403A HK 1247843 A1 HK1247843 A1 HK 1247843A1
Authority
HK
Hong Kong
Prior art keywords
oral administration
active agent
therapeutically active
formulations
snac
Prior art date
Application number
HK18107403.6A
Other languages
English (en)
Inventor
Gregory Burshtein
Ariel ROTHNER
Phillip M. SCHWARTZ
Hillel GALITZER
Original Assignee
Entera Bio Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entera Bio Ltd. filed Critical Entera Bio Ltd.
Publication of HK1247843A1 publication Critical patent/HK1247843A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
HK18107403.6A 2015-02-09 2016-02-09 具有受控吸收曲线的用於口服给药活性剂的制剂 HK1247843A1 (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201562113619P 2015-02-09 2015-02-09
US201562113638P 2015-02-09 2015-02-09
US201562113629P 2015-02-09 2015-02-09
US201562113600P 2015-02-09 2015-02-09
US201562113673P 2015-02-09 2015-02-09
US201562113625P 2015-02-09 2015-02-09
US201562113604P 2015-02-09 2015-02-09
US201562113629P 2015-02-09
US201562113625P 2015-02-09
US201562113604P 2015-02-09
US201562113638P 2015-02-09
US201562113673P 2015-02-09
US201562113600P 2015-02-09
US201562113619P 2015-02-09
PCT/IL2016/050153 WO2016128972A1 (en) 2015-02-09 2016-02-09 Formulations for oral administration of active agents with controlled absorption profile

Publications (1)

Publication Number Publication Date
HK1247843A1 true HK1247843A1 (zh) 2018-10-05

Family

ID=56614456

Family Applications (5)

Application Number Title Priority Date Filing Date
HK18107250.0A HK1247822A1 (zh) 2015-02-09 2016-02-09 用於活性剂口服给药的制剂
HK18107355.4A HK1247835A1 (zh) 2015-02-09 2016-02-09 甲状旁腺功能减退症的治疗
HK18107403.6A HK1247843A1 (zh) 2015-02-09 2016-02-09 具有受控吸收曲线的用於口服给药活性剂的制剂
HK18107372.3A HK1247838A1 (zh) 2015-02-09 2016-02-09 骨质疏松症的治疗
HK18107251.9A HK1247823A1 (zh) 2015-02-09 2016-02-09 骨质疏松的治疗

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK18107250.0A HK1247822A1 (zh) 2015-02-09 2016-02-09 用於活性剂口服给药的制剂
HK18107355.4A HK1247835A1 (zh) 2015-02-09 2016-02-09 甲状旁腺功能减退症的治疗

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK18107372.3A HK1247838A1 (zh) 2015-02-09 2016-02-09 骨质疏松症的治疗
HK18107251.9A HK1247823A1 (zh) 2015-02-09 2016-02-09 骨质疏松的治疗

Country Status (9)

Country Link
US (8) US20180036234A1 (zh)
EP (5) EP3256149A4 (zh)
JP (6) JP6925970B2 (zh)
CN (5) CN114949185A (zh)
CA (3) CA2975710C (zh)
HK (5) HK1247822A1 (zh)
IL (7) IL283258B2 (zh)
MX (2) MX2017010220A (zh)
WO (5) WO2016128973A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
CN106117343B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
CA2868188A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
US20180036234A1 (en) * 2015-02-09 2018-02-08 Entera Bio Ltd. Treatment of bone fractures and defects
KR20190039768A (ko) 2016-08-17 2019-04-15 엔테라 바이오 리미티드 활성 물질의 경구 투여용 제형
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
TWI821541B (zh) * 2019-03-08 2023-11-11 奧孟亞股份有限公司 Pth類似物之口服製劑及治療
EP4025240B1 (en) * 2019-09-03 2024-10-30 Amgen Inc. Il-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
CN114306249A (zh) * 2020-09-28 2022-04-12 深圳翰宇药业股份有限公司 一种特立帕肽冻干药物组合物及其制备方法
US12251208B2 (en) * 2020-11-30 2025-03-18 International Business Machines Corporation Time controlled medication
CN114288388B (zh) * 2022-01-25 2023-11-03 华中科技大学同济医学院附属协和医院 网膜素在制备炎症性肠病治疗药物中的应用
WO2023161935A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone
WO2023161933A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
EP4482513A4 (en) * 2022-02-24 2026-02-18 Entera Bio Ltd FORMULATIONS COMPRISING AN ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF GLUCAGON-TYPE PEPTIDE-2
KR20240150507A (ko) * 2022-02-24 2024-10-15 엔테라 바이오 리미티드 글루카곤 유사 펩타이드-1 및 이의 유사체의 경구 투여를 위한 산 중화 중합체를 포함하는 제형
IL315198A (en) * 2022-02-24 2024-10-01 Entera Bio Ltd Formulations comprising acid-neutralizing polymer for oral administration of active agents
WO2023161938A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide
WO2023161936A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
WO2025046590A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations for oral administration of active agents
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents
WO2025146144A1 (zh) * 2024-01-05 2025-07-10 成都国为生物医药有限公司 一种地非法林的口服药物组合物
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360793A (en) * 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
CN1162917A (zh) * 1994-10-07 1997-10-22 伯温德药品服务公司 肠内涂层组合物，用其涂覆的方法和涂覆制品
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220301C (en) * 1995-06-02 2006-02-21 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
JP3880093B2 (ja) 1995-08-08 2007-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
WO1998009645A1 (en) * 1996-09-04 1998-03-12 Dott Research Laboratory Peptide-containing drug compositions for oral administration
EP0986395A4 (en) 1997-05-14 2004-12-01 Aventis Pharm Prod Inc PEPTIDE ANALOGS OF THE PARATHYROID HORMONE
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
CA2364849A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4588221B2 (ja) 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
IL149337A0 (en) 1999-11-05 2002-11-10 Emisphere Tech Inc Phenoxy carboxylic acid compounds and compositions for delivering active agents
CA2395993A1 (en) * 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
KR20040030120A (ko) * 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
WO2003045306A2 (en) 2001-11-13 2003-06-05 Emisphere Technologies, Inc. Phenoxy amine compounds and compositions for delivering active agents
AU2002352974A1 (en) * 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
KR20040073495A (ko) 2001-12-19 2004-08-19 가부시키가이샤산와카가쿠켄큐쇼 방출제어형 성형품
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TWI307279B (en) * 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
KR20060105735A (ko) 2003-07-04 2006-10-11 니코메드 덴마크 에이피에스 경구용 부갑상선 호르몬 함유 약학 조성물
JP2005281231A (ja) 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口ｄｄｓ製剤
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
EP1830791B1 (en) 2004-11-19 2014-09-10 GlaxoSmithKline LLC Pharmaceutical product
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US20080153779A1 (en) * 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5123471B2 (ja) 2005-08-18 2013-01-23 帝人ファーマ株式会社 用量調整が容易な製剤
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
JP2009515993A (ja) 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
US20070178155A1 (en) * 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
RU2437662C2 (ru) 2006-04-07 2011-12-27 Меррион Рисерч Iii Лимитед Твердая пероральная лекарственная форма, содержащая усилитель
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2007372B1 (en) 2006-04-18 2015-03-04 Emisphere Technologies, Inc. Dialkyl ether delivery agents
US8019481B2 (en) * 2006-12-12 2011-09-13 Horiba Stec, Co., Ltd. Flow rate ratio control device
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
US20100303901A1 (en) * 2007-04-26 2010-12-02 Eyal Shimoni Oral delivery of proteins and peptides
JP2010539096A (ja) * 2007-09-11 2010-12-16 オラヘルス コーポレーション 咽喉、食道及び胃の治療のための局所的に活性である成分を放出する接着トローチ
WO2009080764A2 (en) 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
IT1393244B1 (it) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
US9186412B2 (en) * 2008-08-18 2015-11-17 Entera Bio Ltd. Methods and compositions for oral administration of insulin
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011128424A1 (en) 2010-04-16 2011-10-20 Novartis Ag Methods and compositions for improving implant osseointegration
MX377589B (es) * 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US20130224300A1 (en) 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
WO2013067309A1 (en) * 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
US20180036234A1 (en) 2015-02-09 2018-02-08 Entera Bio Ltd. Treatment of bone fractures and defects
KR20190039768A (ko) 2016-08-17 2019-04-15 엔테라 바이오 리미티드 활성 물질의 경구 투여용 제형
JP7419862B2 (ja) 2020-02-14 2024-01-23 株式会社リコー 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置

Also Published As

Publication number Publication date
EP3256153A4 (en) 2018-11-21
JP2018504444A (ja) 2018-02-15
IL292218B2 (en) 2024-10-01
EP3256152A1 (en) 2017-12-20
CA2975710A1 (en) 2016-08-18
EP3256114A1 (en) 2017-12-20
EP3256114A4 (en) 2018-11-21
IL253804A0 (en) 2017-09-28
CN113694190A (zh) 2021-11-26
CN114949185A (zh) 2022-08-30
IL303216A (en) 2023-07-01
HK1247823A1 (zh) 2018-10-05
CN113730556A (zh) 2021-12-03
EP3256113B1 (en) 2025-04-02
US20180036382A1 (en) 2018-02-08
CA2975676A1 (en) 2016-08-18
US20180021272A1 (en) 2018-01-25
MX2017010220A (es) 2018-02-21
HK1247822A1 (zh) 2018-10-05
EP3256149A1 (en) 2017-12-20
US20240181020A1 (en) 2024-06-06
JP2023055902A (ja) 2023-04-18
EP3256113A1 (en) 2017-12-20
MX2022014313A (es) 2022-12-07
EP3256152A4 (en) 2018-11-14
WO2016128972A1 (en) 2016-08-18
IL292417A (en) 2022-06-01
WO2016128973A1 (en) 2016-08-18
IL292218A (en) 2022-06-01
IL283258A (en) 2021-07-29
EP3256113A4 (en) 2018-11-14
US10583177B2 (en) 2020-03-10
CA2975578A1 (en) 2016-08-18
CN113694190B (zh) 2024-05-07
WO2016128970A1 (en) 2016-08-18
US20200138913A1 (en) 2020-05-07
WO2016128971A1 (en) 2016-08-18
HK1247835A1 (zh) 2018-10-05
US20180036234A1 (en) 2018-02-08
IL253803B (en) 2021-06-30
BR112017017112A2 (pt) 2018-04-03
CN113713090A (zh) 2021-11-30
US20240398904A1 (en) 2024-12-05
JP7775239B2 (ja) 2025-11-25
CN107427481A (zh) 2017-12-01
JP6925970B2 (ja) 2021-08-25
EP3256149A4 (en) 2019-08-14
IL253802B (en) 2022-06-01
IL253802A0 (en) 2017-09-28
IL292417B2 (en) 2024-12-01
IL283258B1 (en) 2023-07-01
JP2021176913A (ja) 2021-11-11
CN113713090B (zh) 2023-06-02
US12076373B2 (en) 2024-09-03
CA3011657A1 (en) 2016-08-18
JP6925969B2 (ja) 2021-08-25
IL292218B1 (en) 2024-06-01
IL253804B (en) 2022-05-01
WO2016128974A1 (en) 2016-08-18
EP3256153A1 (en) 2017-12-20
IL253803A0 (en) 2017-09-28
JP2023100920A (ja) 2023-07-19
IL292417B1 (en) 2024-08-01
JP2021176914A (ja) 2021-11-11
HK1247838A1 (zh) 2018-10-05
CA3011654A1 (en) 2016-08-18
US20180028622A1 (en) 2018-02-01
JP2018504445A (ja) 2018-02-15
US20180050096A1 (en) 2018-02-22
JP7275207B2 (ja) 2023-05-17
IL283258B2 (en) 2023-11-01
CA2975710C (en) 2023-08-08

Similar Documents

Publication Publication Date Title
HK1247843A1 (zh) 具有受控吸收曲线的用於口服给药活性剂的制剂
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
CR20210108A (es) Benzamidas sustituidas con 1, 3-tiazol-2-ilo
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
HK1222297A1 (zh) 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途
MX2020003381A (es) Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
WO2014186742A3 (en) Anhydrous hydrogel composition
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2013003635A (es) Compuestos de n-heteroarilo.
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
HK1231390A1 (zh) 用於局部给药的药用组合物
MX2013006187A (es) Composiciones farmaceuticas.
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo